GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » 3-Year EPS without NRI Growth Rate

Aurinia Pharmaceuticals (FRA:IKAP) 3-Year EPS without NRI Growth Rate : 14.70% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals 3-Year EPS without NRI Growth Rate?

Aurinia Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was €-0.17.

During the past 3 years, the average EPS without NRI Growth Rate was 14.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 2.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was -8.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Aurinia Pharmaceuticals was 55.00% per year. The lowest was -287.60% per year. And the median was 4.90% per year.


Competitive Comparison of Aurinia Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Aurinia Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurinia Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.



Aurinia Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Aurinia Pharmaceuticals  (FRA:IKAP) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Aurinia Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurinia Pharmaceuticals (FRA:IKAP) Business Description

Traded in Other Exchanges
Address
4464 Markham Street, Suite 1203, Victoria, BC, CAN, V8Z 7X8
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.

Aurinia Pharmaceuticals (FRA:IKAP) Headlines

No Headlines